Effects of anacetrapib in patients with atherosclerotic vascular disease by Bowman, L, Hopewell, J, Chen, F, Wallendszus, K, Stevens, W, Collins, R, Wiviott, S, Cannon, C, Braunwald, E, Sammons, E, Landray, M

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities by Loesch, DP, Garg, M, Matelska, D, Vitsios, D, Jiang, X, Ritchie, SC, Sun, BB, Runz, H, Whelan, CD, Holman, RR, Mentz, RJ, Moura, FA, Wiviott, SD, Sabatine, MS, Udler, MS, Gause-Nilsson, IA, Petrovski, S, Oscarsson, J, Nag, A, Paul, DS, Inouye, M

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities by Douglas P. Loesch, Manik Garg, Dorota Matelska, Dimitrios Vitsios, Xiao Jiang, Scott C. Ritchie, Benjamin B. Sun, Heiko Runz, Christopher D. Whelan, Rury R. Holman, Robert J. Mentz, Filipe A. Moura, Stephen D. Wiviott, Marc S. Sabatine, Miriam S. Udler, Ingrid A. Gause-Nilsson, Slavé Petrovski, Jan Oscarsson, Abhishek Nag, Dirk S. Paul, Michael Inouye

Get full text

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis by Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

2017 cardiovascular and stroke endpoint definitions for clinical trials by Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials by Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MTT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ, Standardized Data Collection For Cardiovascular Trials Initiative (Scti)

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease by Sammons, E, Hopewell, JC, Chen, F, Stevens, W, Wallendszus, K, Valdes-Marquez, E, Dayanandan, R, Knott, C, Murphy, K, Wincott, E, Baxter, A, Goodenough, R, Lay, M, Hill, M, Macdonnell, S, Fabbri, G, Lucci, D, Fajardo-Moser, M, Brenner, S, Hao, D, Zhang, H, Liu, J, Wuhan, B, Mosegaard, S, Herrington, W, Wanner, C, Angermann, C, Ertl, G, Maggioni, A, Barter, P, Mihaylova, B, Mitchel, Y, Blaustein, R, Goto, S, Tobert, J, DeLucca, P, Chen, Y, Chen, Z, Gray, A, Haynes, R, Armitage, J, Baigent, C, Wiviott, S, Cannon, C, Braunwald, E, Collins, R, Bowman, L, Landray, M